Edition:
United Kingdom

People: CareDx Inc (CDNA.OQ)

CDNA.OQ on NASDAQ Stock Exchange Global Market

32.70USD
23 Jul 2019
Change (% chg)

-- (--)
Prev Close
$32.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
263,299
52-wk High
$41.27
52-wk Low
$11.93

Goldberg, Michael 

Mr. Michael D. Goldberg is an Independent Chairman of the Company. Mr. Goldberg has served as a director and chairman of the Board of Directors of DNAnexus, Inc., and as an advisor to other private life science companies since May 2011. Mr. Goldberg has also served on the Board of Directors for eHealth, Inc. since 1999. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, adventure capital firm. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as its chairman until August 2001 and as its chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as its Chief Executive Officer until its sale in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm of Sevin Rosen anagement Company from 1985 to 1987, where he established the firm’s life science practice, and director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the Board of Directors of numerous companies in the biotech and health sciences industry. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic and public policy institutions in biotechnology and finance, including the Board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the Board of the Western Association of Venture Capitalists, the Advisory Boards for the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a B.A. from Brandeis University and an M.B.A. from the Stanford Graduate School of Business.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 171,045
Long-Term Incentive Plans, USD --
All Other, USD 157,623
Fiscal Year Total, USD 328,668

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Goldberg

328,668

Reginald Seeto

3,168,380

Peter Maag

5,231,390

Michael Bell

2,095,010

Sasha King

--

James Yee

697,495
As Of  31 Dec 2018